1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine: Negative Control in Src Kinase Signaling Pathway Research

Executive Summary: 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (CAS: 5334-30-5) is a small molecule negative control for Src kinase inhibitor PP 2, supporting high-fidelity kinase signaling studies (APExBIO). It features a molecular weight of 211.22 with a chemical formula of C11H9N5, is DMSO-soluble, and is supplied at ≥98% purity. This compound enables the separation of Src-specific from nonspecific effects in cell signaling and cancer biology research (internal source). Its specificity was confirmed in vascular contractility assays and kinase pathway benchmarks (Shvetsova et al., 2025). Usage is strictly for research purposes and not for diagnostic or therapeutic applications.

Biological Rationale

Protein tyrosine kinases, including Src family kinases, are central to cell signaling pathways that govern growth, differentiation, and survival. Aberrant Src kinase activity is implicated in cancer, vascular disease, and immune regulation (Shvetsova et al., 2025). Pharmacological inhibition of Src kinases is widely used to dissect their role in signal transduction and to validate therapeutic targets. However, off-target effects of kinase inhibitors can confound interpretation. Negative control compounds, like 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, are chemically similar but lack specific inhibitory activity, allowing researchers to distinguish Src-dependent effects from non-specific responses (internal link). This approach is essential for robust pathway mapping, especially in studies of vascular smooth muscle contraction and cancer cell signaling.

Mechanism of Action of 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine acts as a negative control by mimicking the chemical scaffold of PP 2, a potent Src kinase inhibitor, without inhibiting Src kinase enzymatic activity. This enables discrimination between Src-mediated and off-target pharmacological effects in cellular and biochemical assays (APExBIO). It does not significantly inhibit L-type Ca²⁺ channels or other kinases at concentrations up to 10 μM (Shvetsova et al., 2025). The compound is DMSO-soluble, facilitating its use in cell-based and in vitro kinase assays. By serving as a negative control, it validates the specificity of Src kinase pathway modulation and supports mechanistic studies in vascular and cancer biology (internal link).

Evidence & Benchmarks

• PP 2 (10 μM) reduces methoxamine-induced arterial contraction in early postnatal rat saphenous arteries, while 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine shows no such effect, confirming lack of Src inhibition (Shvetsova et al., 2025).
• 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine does not impact basal or NADPH-induced ROS production in vascular tissue under physiological conditions (Shvetsova et al., 2025).
• The compound is supplied at ≥98% purity, with batch-specific COA and MSDS, ensuring reproducibility in kinase and signal transduction studies (APExBIO product page).
• Internal benchmarking demonstrates it enables distinction between Src-dependent and off-target effects in kinase assays, outperforming generic vehicle controls (internal benchmark).

Applications, Limits & Misconceptions

1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is indispensable for:

• Validating Src kinase-dependent mechanisms in cancer biology, vascular contractility, and cell signaling studies.
• Dissecting specific protein tyrosine kinase inhibition from off-target pharmacology in complex biological models (internal link).
• Supporting reproducibility in pharmacological and mechanistic research, especially in signal transduction pathways.

This article extends previous analyses by providing updated evidence from vascular contractility models and recent peer-reviewed studies, clarifying boundaries of specificity compared to older sources (see related article).

Common Pitfalls or Misconceptions

• Not a diagnostic or therapeutic agent: The compound is for research use only and not for clinical application (APExBIO).
• Does not inhibit Src kinase: It is structurally similar to PP 2 but lacks Src kinase inhibitory activity.
• Inactive against L-type Ca²⁺ channels and general ROS pathways: Unlike some kinase inhibitors, it does not affect these pathways at standard research concentrations (Shvetsova et al., 2025).
• Not recommended for long-term solution storage: Solutions should be prepared fresh and used promptly due to stability limitations.
• Requires chemical controls: For robust experimental design, always pair with positive controls and vehicle treatments.

Workflow Integration & Parameters

For optimal use, 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (B7190) should be stored at -20°C and shipped with blue ice (product specification). Prepare solutions in DMSO at a final concentration compatible with cellular or biochemical assays (commonly ≤10 μM). Avoid repeated freeze-thaw cycles and do not store solutions for extended periods. Integrate into workflows as a matched negative control alongside PP 2 or other kinase inhibitors. Confirm cell signaling outputs (e.g., phosphorylation status, contractility) to validate specificity in experimental readouts. Detailed assay protocols and safety documentation are provided with each batch by APExBIO.

Conclusion & Outlook

1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is a gold-standard negative control in Src kinase signaling research. Its use ensures experimental specificity and reproducibility, particularly in vascular and cancer biology contexts. Current evidence supports its inertness in Src-dependent and L-type Ca²⁺ channel-mediated pathways, with no effect on ROS generation in arterial models (Shvetsova et al., 2025). APExBIO provides comprehensive quality control, making this compound a cornerstone for kinase inhibitor control studies. Ongoing innovations in kinase signaling research will further rely on validated negative controls to elucidate molecular mechanisms in health and disease.